Page last updated: 2024-12-06

hydroxymaprotilin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hydroxymaprotilin: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID38207
CHEMBL ID1213009
SCHEMBL ID121940
MeSH IDM0088873

Synonyms (27)

Synonym
CHEMBL1213009
oxaprotilinum [inn-latin]
alpha-((methylamino)methyl)-9,10-ethanoanthracene-9(10h)-ethanol
9,10-ethanoanthracene-9(10h)-ethanol, alpha-((methylamino)methyl)-
oxaprotilin
oxaprotilina [inn-spanish]
hydroxymaprotilin
3-(9,10-ethano-9,10-dihydro-9-anthryl)-1-methylamino-2-propanol
oxaprotiline
oxaprotiline [inn]
56433-44-4
bdbm85218
cas_39022-39-4
unii-3v3z2hk4ls
(+-)-oxaprotiline
3v3z2hk4ls ,
oxaprotilina
oxaprotilinum
oxaprotiline [who-dd]
(+/-)-.alpha.-((methylamino)methyl)-9,10-ethanoanthracene-9(10h)-ethanol
SCHEMBL121940
levoprtiline
09,10-ethanoanthracene-9(10h)-ethanol, alpha-((methylamino)methyl)-
Q7115112
1-(methylamino)-3-(1-tetracyclo[6.6.2.02,7.09,14]hexadeca-2,4,6,9,11,13-hexaenyl)propan-2-ol
DTXSID40866561
AKOS040747238

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The elimination of levoprotiline from blood was independent of the dosing route, the half-life being 18."( Pharmacokinetics of the antidepressant levoprotiline after intravenous and peroral administration in healthy volunteers.
Ackermann, R; Bieck, PR; Dieterle, W; Kaiser, G; Reimann, IW, 1992
)
0.28

Bioavailability

ExcerptReferenceRelevance
" The method is suitable for use in pharmacokinetic and bioavailability studies of levoprotiline in humans."( Determination of the antidepressant levoprotiline and its N-desmethyl metabolite in biological fluids by gas chromatography/mass spectrometry.
Ackermann, R; Dieterle, W; Kaiser, G; Schueller, F, 1991
)
0.28

Dosage Studied

ExcerptRelevanceReference
" Its plasma levels (40 ng/ml) were one third to one half of the values obtained with maprotiline in the same daily dosage (150 mg)."( [Results of a clinical trial of levoprotiline].
Bornová, L; David, I; Filip, V; Höschl, C; Karen, P; Seifertová, D, 1992
)
0.28
" The elimination of levoprotiline from blood was independent of the dosing route, the half-life being 18."( Pharmacokinetics of the antidepressant levoprotiline after intravenous and peroral administration in healthy volunteers.
Ackermann, R; Bieck, PR; Dieterle, W; Kaiser, G; Reimann, IW, 1992
)
0.28
" The study was conducted over a period of 28 days and the dosage of each substance, after being gradually increased, was stabilized at 150 mg."( CGP 12.103 A versus clomipramine in the treatment of depressed inpatients--results of a double-blind study.
Binz, U; Hole, G; Steiner, B; Wendt, G; Wolfersdorf, M, 1988
)
0.27
"In a double-blind study on 38 unselected depressive inpatients (19 per group) suffering from endogenous and psychogenic depression, oxaprotiline, a new tetracyclic compound, a hydroxylized maprotiline with a highly selective norepinephrine reuptake inhibition, was compared with clomipramine over a period of 28 days in a daily dosage of 150 mg."( Double-blind study of oxaprotiline versus clomipramine in the treatment of depressive inpatients.
Binz, U; Hole, G; Metzger, R; Wendt, G; Wolfersdorf, M, 1987
)
0.27
" Oxaprotiline was given in a dosage up to 225 mg over a period of 28 days."( Oxaprotiline in the treatment of endogenous depressed inpatients an early clinical trial.
Blaschke, D; Dieterle, D; Laakmann, G; Schmauss, M, 1985
)
0.27
"), shifted the dose-response relationships to the right for each of the antidepressant agents (dothiepin, amitriptyline, sibutramine, (+)-oxaprotiline and paroxetine)."( The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds.
Gray, AM; Sewell, RD; Spencer, PS, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (100)

TimeframeStudies, This Drug (%)All Drugs %
pre-199051 (51.00)18.7374
1990's43 (43.00)18.2507
2000's5 (5.00)29.6817
2010's1 (1.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.19

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.19 (24.57)
Research Supply Index4.94 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.19)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials28 (25.23%)5.53%
Reviews3 (2.70%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other80 (72.07%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]